Masimo (NASDAQ:MASI) Updates Q4 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its fourth quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 1.540- for the period, compared to the consensus EPS estimate of 1.440. The company issued revenue guidance of $411.0 million-$411.0 million, compared to the consensus revenue estimate of $407.1 million.

Masimo Trading Down 1.8%

Masimo stock traded down $2.46 during midday trading on Monday, hitting $136.46. 20,235 shares of the stock were exchanged, compared to its average volume of 563,616. The stock has a market capitalization of $7.33 billion, a PE ratio of -12.95, a P/E/G ratio of 1.42 and a beta of 1.26. Masimo has a 52 week low of $125.94 and a 52 week high of $194.88. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $140.07 and a two-hundred day simple moving average of $147.06.

Masimo (NASDAQ:MASI) last issued its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The company had revenue of $617.00 million during the quarter. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. Equities research analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. BTIG Research boosted their target price on Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Wells Fargo & Company restated an “overweight” rating and set a $190.00 target price on shares of Masimo in a research note on Friday, December 5th. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Monday, December 1st. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $189.40.

Institutional Investors Weigh In On Masimo

Several hedge funds have recently bought and sold shares of the stock. Viking Global Investors LP purchased a new position in Masimo during the second quarter worth about $129,096,000. Alyeska Investment Group L.P. increased its holdings in shares of Masimo by 21.7% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,381,085 shares of the medical equipment provider’s stock worth $203,779,000 after buying an additional 246,595 shares during the last quarter. Bank of America Corp DE raised its position in shares of Masimo by 113.0% during the 3rd quarter. Bank of America Corp DE now owns 405,061 shares of the medical equipment provider’s stock valued at $59,767,000 after buying an additional 214,885 shares during the period. Ameriprise Financial Inc. lifted its holdings in Masimo by 86.3% in the second quarter. Ameriprise Financial Inc. now owns 394,487 shares of the medical equipment provider’s stock valued at $66,361,000 after acquiring an additional 182,701 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Masimo by 1,760.7% in the third quarter. Marshall Wace LLP now owns 134,122 shares of the medical equipment provider’s stock worth $19,790,000 after acquiring an additional 126,914 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.